Ascletis Pharma saw the highest growth of 0.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Ascletis Pharma’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Ascletis Pharma has been focused on protecting inventions in Australia(AU) with one publication in Q2 2024
The Australia(AU) Patent Office dominates the patent grants with nearly 100% of grants. The European Patent Office(EPO), South Korea(KR), United States(US), and Australia(AU) patent Office are among the top ten patent offices where Ascletis Pharma is filings its patents. Among the top granted patent authorities, Ascletis Pharma has 100% of its grants in Australia(AU).
Gilead Sciences and Roche could be the strongest competitors for Ascletis Pharma
Non alcoholic fatty liver disease (nafld) related patents lead Ascletis Pharma portfolio followed by non-alcoholic steatohepatitis (nash), and liver diseases
Ascletis Pharma has highest number of patents in non alcoholic fatty liver disease (nafld) followed by non-alcoholic steatohepatitis (nash), liver diseases, mobiles, hand-helds, pdas, smartphones.
For comprehensive analysis of Ascletis Pharma's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

